Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018

NEXT STORY
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
PREV STORY
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19

author_avatar
NASDAQ Market News

Moleculin to Present at the Life Sciences Investor Forum

author_avatar
NASDAQ Market News

Sharps Compliance Reports Fiscal 2018 Third Quarter Results

author_avatar
NASDAQ Market News